论文部分内容阅读
目的:研究视黄醇结合蛋白4(retinol binding protein 4,RPB4)基因rs3758539G-803A和rs10882283T-179G多态性对中国人群2型糖尿病患者使用罗格列酮疗效的影响。方法:使用PCR-RFLP方法对472名2型糖尿病患者和198名健康对照者进行RPB4基因G-803A和T-179G多态性位点的基因分型。随机选择42名携带不同RBP4基因型的2型糖尿病患者给予12周每天4 mg的罗格列酮口服治疗。检测用药前后空腹血糖(fasting plasma glucose,FPG)、餐后血糖(postprandial plasma glucose,PPG)、空腹胰岛素(fastingserum insulin,FINS)、餐后胰岛素(postprandial serum insulin,PINS)、糖化血红蛋白(glycated hemoglobin,HbAlc)、甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low-density lipoprotein-cholesterol,LDL-c))和高度脂蛋白胆固醇(high-density lipoprotein-cholesterol,HDL-c)等指标。结果:携带RBP4 G-803A GG基因型的患者其TG和LCL-c水平显著低于GA+AA基因型患者。携带T-179G TT基因型的患者其腰臀比、FPG和FINS值显著低于TG+GG基因型患者。携带RBP4 G-803A GG基因型的患者服用罗格列酮后FPG和FINS下降值优于GA+AA基因型患者。携带T-179G TG+GG基因型的患者服用罗格列酮后的HbAlc下降值优于TT基因型患者。结论:RBP4 G-803A和T-179G基因多态性与2型糖尿病相关且影响罗格列酮的疗效。
Objective: To investigate the effect of rs3758539G-803A and rs10882283T-179G polymorphisms of retinol binding protein 4 (RPB4) gene on rosiglitazone in Chinese patients with type 2 diabetes mellitus. METHODS: Genotyping of the RPB4 G-803A and T-179G polymorphisms was performed in 472 patients with type 2 diabetes mellitus and 198 healthy controls using PCR-RFLP. Forty-two patients with type 2 diabetes who had different RBP4 genotypes were randomized to oral administration of rosiglitazone 4 mg daily for 12 weeks. The levels of fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting insulin insulin (FINS), postprandial serum insulin (PINS), glycated hemoglobin HbAlc, triglyceride (TG), low-density lipoprotein-cholesterol (LDL-c) and high-density lipoprotein-cholesterol (HDL- Results: The levels of TG and LCL-c in patients with GG genotype of RBP4 G-803A were significantly lower than those in patients with GA + AA genotype. Patients with T-179G TT genotype had lower WHR, FPG and FINS values than those with TG + GG genotype. Patients with RBG4 G-803A GG genotype had better FPG and FINS declines than those with GA + AA genotype after taking rosiglitazone. Patients with T-179G TG + GG genotype had better HbAlc reduction than those with TT genotype after taking rosiglitazone. Conclusion: The polymorphisms of RBP4 G-803A and T-179G are associated with type 2 diabetes and affect the efficacy of rosiglitazone.